Key result
Depressed mood is linked to ~7% lower two-year DFS in gynecological cancer.
Why the study?
The study was conducted to evaluate the relationship between depressed mood and gynecological cancer outcomes and to identify risk factors for cancer aggravation.
Does depressed mood increase the risk of cancer aggravation in gynecological cancer patients?
Cohort (n=217)
No
Does depressed mood increase the risk of cancer aggravation in gynecological cancer patients?
Absolute Event Rate: 86.4% vs 93.6%
p-value: p=0.006
Depressed mood is associated with a significantly lower two-year disease-free survival in patients with gynecological cancer, highlighting the importance of psychological management.
Depressed mood was associated with lower DFS in gynecological cancer; hypothesis-generating and requires prospective trials before informing practice.
Background: The aim of this study was to evaluate the relationship between depressed mood and gynecological cancer outcomes, identifying risk factors for cancer aggravation. Methods: This study was a retrospective analysis of gynecological cancer patients (January 2020–August 2022) at Korea University Anam Hospital using Patient Health Questionnaire-9 (PHQ-9). Patients were classified into non-depressed mood (NDM)- and depressed mood (DM)-based scores. Statistical analysis was performed using Student’s t-test, chi-square test, Fisher’s exact test, Kaplan–Meier analysis, and Cox regression analyzing using SPSS. Results: Of the 217 participants, the NDM group comprised 129 patients, and the DM group comprised 88. The two-year disease-free survival (DFS) rates showed significant differences (NDM, 93.6%; DM 86.4%; p = 0.006), but overall survival (OS) did not (p = 0.128). Patients with stage 3 or higher cancer, undergoing five or more chemotherapies, experiencing post-chemotherapy side effects, and depressed mood had an increased risk of cancer aggravation. Conclusions: Appropriate treatment of depressed mood, as well as adequate treatment for advanced gynecological cancer patients, those with numerous CTx., and those with post-CTx. side effects, may contribute to reducing the risk of cancer aggravation.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) conducted a cohort in Gynecological cancer (n=217). Depressed mood vs. Non-depressed mood was evaluated on Two-year disease-free survival (DFS) (p=0.006). Depressed mood was associated with a significantly lower two-year disease-free survival rate compared to non-depressed mood in patients with gynecological cancer (86.4% vs 93.6%; p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: